Novo Nordisk has reported that its 2.4mg dosage of semaglutide (Wegovy) demonstrated a reduction in liver injury (steatohepatitis) among patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced liver scarring (fibrosis), even at low levels of weight loss. MASH is a progressive metabolic disease affecting the liver and is estimated to impact more than 250 million people globally. If left untreated, the condition can lead to irreversible liver damage and, ulti

iStock, Ekaterina Chergik Only one clinical-stage asset from the ProfoundBio acquisition remains in development: The antibody-drug conjugate Rina-S, in late-stage studies for ovarian and endometrial cancer. Genmab has scrapped another antibody-drug conjugate picked up in its $1.8 billion acquisition of ProfoundBio last year, continuing the pruning of that company’s molecules. The asset, dubbed GEN1160, was in a Phase I/II study assessing its safety and efficacy for blood cancers and solid tum

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, HONG KONG, JAPAN, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES Mendus AB (publ) (“Mendus” or the “Company”) hereby announces its intention to carry out a directed issue of shares of

Pivotal Phase III liver cancer study enrolling in Europe and Israel RAMAT GAN, Israel, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, announced today that a patient treated with Namodenoson has reached an overall survival of 9 years to date with complete response to treatment. The patient, who suffered from advanced liver

– REDEMPLO is the first and only FDA-approved medicine to be studied in patients with genetically confirmed and clinically diagnosed FCS – People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, often resulting in a reduced quality of life – The FDA approval is based on positive results from the Phase 3 PALISADE study where REDEMPLO significantly reduced triglycerides from baseline and lowered the n

iStock, SvetaZi The introduction of AbbVie’s hepatitis C drugs in 2014 forced Gilead’s hand in the fight for market dominance in hepatitis C. A similar dynamic is now playing out between Eli Lilly and Novo Nordisk in the obesity space, with some key differences. Almost 10 years before Novo Nordisk and Eli Lilly’s cutthroat battle for control of the obesity market, AbbVie and Gilead duked it out over a highly effective class of hepatitis C drugs. As Novo and Lilly’s drug prices come on full disp

iStock, Chitraporn Nakorn With positive data from the Phase III HERIZON-GEA-01 study, Zymeworks and Jazz Pharmaceuticals will approval application for Ziihera in the first half of 2026 for the treatment of gastroesophageal adenocarcinoma. Jazz Pharmaceuticals and Zymeworks’ HER2 bispecific antibody Ziihera significantly improved progression-free survival in a Phase III study of patients with gastroesophageal adenocarcinoma, clearing the way for a regulatory filing. The partners plan to suppleme

First Patient Dosed at The Ohio State University Wexner Medical Center in this Multi-Center Trial Active component of HCW9302 is interleukin-2 -- cytokine that maintains proper numbers and functions of regulatory T cells to control excessive inflammation Gateway to development of a first-in-kind immunotherapeutic for autoimmune and pro-inflammatory diseases MIRAMAR, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage bi

iStock, Love Employee The industry’s ability to generate a return on billions of dollars of investment rests on a heavily regulated supply chain defined by time-pressured logistics. Some of the world’s biggest drugmakers have invested heavily in radiopharmaceuticals in recent years, striking multi-billion dollar deals to secure assets with the potential to transform cancer treatment. Frontrunner Novartis recently opened a 10,000-square-foot facility as part of a $23 billion investment in U.S.

InflaRx – a biopharmaceutical company developing anti-inflammatory therapeutics targeting the complement system – has announced positive topline data from its phase 2a basket study evaluating INF904 as a potential treatment for hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). HS and CSU are chronic inflammatory skin conditions characterised by rashes, abscesses, inflammation and scarring. INF904 is an orally administered, small molecule inhibitor of the C5a receptor (C5aR1)